Trial
NCT01010542
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Pfizer
Collaborators
—
Condition
Plaque Psoriasis
Intervention
ILV-095 300 mg in a 4 to 1 ratio
Why stopped
See termination reason in detailed description.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-03